Graftskin data show improved wound healing:
This article was originally published in Clinica
Executive Summary
Organogenesis has moved closer to submission for US approval of its Graftskin human skin product after presenting analysis of trial data. Results from the prospective, randomised trial presented at the Symposium on Advanced Woundcare in San Diego this month, show that Graftskin was 60% more effective than standard compression in closing wounds completely in a median time of 57 days compared with 181 for compression. The company is completing analysis of secondary endpoints, including factors such as oedema, pain and exudate, in preparation for a submission for marketing approval.